Trial Profile
Prospective phase II trial using Capecitabine and Trastuzumab for therapy of female patients with cerebral metastasizing, HER2-overexpressing breast cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Jul 2011
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Trastuzumab (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms HERXEL
- 12 Jul 2011 New trial record